An Uncontrolled Phase II, Multi Center Trial Evaluating Antitumor Efficacy and Safety of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Objective overall tumor response rate calculated as the percentage of patients with complete and partial responses
At baseline and every 2 cycles during the treatment period
Bayer Study Director
Study Director
Bayer
United States: Food and Drug Administration
100386
NCT00044564
December 2001
January 2003
Name | Location |
---|---|
Medical College of Wisconsin | Milwaukee, Wisconsin 53226 |
St. Louis University Health Sciences Center | Saint Louis, Missouri 63110-0250 |
Robert Wood Johnson Medical School | New Brunswick, New Jersey 08903 |
University of Utah | Salt Lake City, Utah |
Washington University | St. Louis, Missouri 63110 |
Scripps Clinic - Torrey Pines | La Jolla, California 92037 |
Medical Consultants, PC | Muncie, Indiana 47304 |
Ochsner Foundation Hospital | New Orleans, Louisiana 70121-2484 |
University of Maryland Hospital System | Baltimore, Maryland 21201-1595 |
Urology Associates | Greenbelt, Maryland 20770 |
Harper University Hospital | Detroit, Michigan 48201-9027 |
Providence Hospital | Southfield, Michigan 48075 |
Hematology-Oncology Centers of the Northern Rockies | Billings, Montana 59101 |